PFE | Weekly | Haru Insights

Pfizer’s Phase 3 trial failure of sigvotatug vedotin in non-small cell lung cancer—a pivotal asset acquired through the $43 billion Seagen deal—has delivered a major setback to its oncology ambitions, undermining confidence in the strategic value of the acquisition.
The upcoming FDA decision in August 2026 on the Padcev + Keytruda combination for bladder cancer stands as the most critical near-term catalyst, with a positive outcome potentially validating Pfizer’s ADC strategy and unlocking substantial commercial upside.

Vyndaqel/Vyndamax’s $1.6 billion Q1 2026 revenue from ATTR-CM showcases Pfizer’s unmatched dominance in high-margin niche therapies, proving its ability to sustain profitability beyond patent expirations.
The EU approval of the Keytruda + Padcev combo confirms Pfizer’s success in leveraging partnerships to deliver clinically and commercially viable oncology solutions despite late-stage failures.
A 6.8%–7.3% dividend yield, combined with disciplined capital allocation and consistent earnings, makes PFE a rare income anchor in a low-rate world, reinforcing long-term investor loyalty.
Strategic acquisitions like Seagen, Biohaven, and Metsera continue to enrich Pfizer’s pipeline with diversified, high-potential assets, suggesting a proactive posture toward future innovation.
The impending FDA decision on Padcev + Keytruda remains a powerful catalyst, with a positive vote poised to revalidate Pfizer’s oncology platform and unlock transformative growth.

Pfizer Inc. (PFE)[Tv]